Accelerating Drug Discovery will increase the Demand of Automated Cell Culture Systems for Pharmaceuticals

According to Precision Business Insights (PBI), the latest report, the automated cell culture market was valued at USD 24.9 billion in 2023 and is expected to grow at 8.4% CAGR from 2024 to 2030. Pharmaceutical companies are increasingly turning to automation to streamline drug discovery pipelines. Automated cell culture systems allow for high-throughput screening, lead optimization, and faster development cycles, ultimately leading to more efficient drug discovery. The alarming rise of chronic diseases like cancer demands innovative research tools. Automated cell culture empowers researchers to conduct complex cell-based assays at a faster pace, paving the way for new therapies to combat these debilitating illnesses. Artificial intelligence is poised to revolutionize cell culture automation. AI-powered systems can analyze complex data sets, automate tedious tasks like cell feeding and passaging, and even provide valuable insights from cell culture experiments. This integration offers researchers a powerful tool to unlock new discoveries.

View Full Report: https://www.precisionbusinessinsights.com/market-reports/automated-cell-culture-market

Automated Cell Culture Market Detailed Segmentation:
Based on the product type, the market is segmented into the following:
• Instruments
• Consumables

Based on the product type, the global automated cell culture market segmented into instruments (automated cell culture systems, bioreactors, culture chambers, incubators, cell counters, others), consumables (reagents, media, sera, disposables, others). The instrument segment holds the majority share of the market at 64.4% in 2023. The instrument segment encompasses a wide range of equipment, from automated liquid handling robots and microplate readers to CO2 incubators and biosafety cabinets. This broad range caters to diverse research needs and allows for a modular approach to automation. While consumables are crucial for cell culture, they are considered a recurring expense. Their market share will likely grow alongside the overall market

Request Sample: https://www.precisionbusinessinsights.com/request-sample/?product_id=430666

Based on the application, the market is segmented into the following:
• Drug Discovery
• Regenerative Medicine
• Cancer Research
• Stem Cell Research
• Biopharmaceutical Production
• Other Applications

Based on the application, the global automated cell culture market segmented into drug discovery, regenerative medicine, cancer research, stem cell research, biopharmaceutical production, other applications. The biopharmaceutical production holds the largest market share at 28.4% in 2023. The demand for automated cell culture technologies is particularly high in biopharmaceutical production due to the need for scalable and reproducible cell culture processes in the manufacturing of biologics such as monoclonal antibodies, vaccines, and cell therapies. Consequently, solutions tailored for biopharmaceutical production applications are expected to dominate a substantial portion of the market.

Based on the end user, the market is segmented into the following:
• Biotechnology & Pharmaceutical Companies
• Research Institutes & Academic Centers
• Contract Research Organizations (CROs)
• Hospitals & Diagnostic Centers

Based on the end user, the global automated cell culture market is segmented into biotechnology & pharmaceutical companies, research institutes & academic centers, contract research organizations (CROs), hospitals & diagnostic centers. Pharmaceutical companies lead with 34.9% market share in 2023, the extensive adoption of automated cell culture technologies in drug discovery, development, and production within the biotechnology and pharmaceutical sectors, companies catering to this segment are likely to hold a leading market share. These entities often invest in cutting-edge automated cell culture systems and consumables to enhance productivity and accelerate drug development timelines.

Based on geography, the market is segmented into the following:
• North America
• Europe
• The Asia Pacific
• Latin America
• MEA

The North America automated cell culture market was around 35.6% in the global automated cell culture market and will grow with a CAGR of 5.6% during the forecasted period. The demand for automated cell culture systems in North America is primarily driven by the biopharmaceutical industry's need for scalable and reproducible cell culture processes. Pharmaceutical companies, biotechnology firms, and research institutions in the region are increasingly investing in automated solutions to streamline drug discovery, development, and bioproduction processes. Moreover, collaborations between industry players and academic institutions, as well as government initiatives supporting life sciences research and innovation, further fuel market growth. North America also benefits from a favorable regulatory environment and substantial investments in healthcare infrastructure, which contribute to the market's expansion. With the increasing prevalence of chronic diseases, the growing demand for biologics, and ongoing advancements in automation technology, the North American automated cell culture market is expected to continue its growth trajectory in the coming years.

Request Methodology: https://www.precisionbusinessinsights.com/request-methodology/?product_id=430666

Product Launch, Mergers, Collaborations, and Agreements are the key Strategies Adopted by Market Players:
The market players in the automated cell culture market adopt a combination of these strategies to stay competitive, drive growth, and capitalize on opportunities in the dynamic pharmaceutical landscape. This includes product launches and collaborations among the key market players to expand their presence in the global automated cell culture market. For instance,

In 2023, GE Healthcare launched cell analyzer 6500HS high-content imaging system, this system combines automated high-throughput imaging with AI-driven analysis, providing valuable tools for cell culture research

In 2021, Sartorius launched the BIOSTAT STR Generation 3 bioreactor platform, featuring enhanced flexibility, scalability, and connectivity for automated cell culture processes in biopharmaceutical production.

In 2021, MilliporeSigma announced a collaboration with Repligen Corporation to provide continuous bioprocessing solutions, leveraging MilliporeSigma's automation expertise in cell culture.

Key players profiles in the automated cell culture market report are Thermo Fisher Scientific Inc. , Sartorius AG, Merck KGaA (MilliporeSigma), PerkinElmer, Inc., Hamilton Company, Pall Corporation, Applikon Biotechnology, Eppendorf AG, Cell Culture Company, InvivoGen

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 - 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to delivering more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.